Clinical Trials

180 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT02960555 2026-04-15

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

61 enrolled

Phase 3 Active not recruiting

Smoldering Multiple Myeloma

NCT03301220 2026-04-13

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 3 FDA

Smoldering Multiple Myeloma

NCT05955508 2026-04-13

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

40 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06140524 2026-04-08

LINKER-MGUS1

116 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT03937635 2026-04-03

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

288 enrolled

Smoldering Multiple Myeloma

NCT07069751 2026-04-03

HiFi-MM

62 enrolled

Smoldering Multiple Myeloma

NCT03236428 2026-03-27

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

42 enrolled 8 charts

Phase NA Not yet recruiting

Smoldering Multiple Myeloma, Paraproteinemias

NCT06987708 2026-03-23

Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers

67 enrolled

Phase 3 Not yet recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT07393282 2026-03-16

LINKER-SMM2

270 enrolled

Phase 1 Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT02886065 2026-03-13

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

19 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT05767359 2026-03-12

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

20 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05014646 2026-03-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

27 enrolled

Phase NA Not yet recruiting

Smoldering Multiple Myeloma

NCT07446777 2026-03-03

FAST-M

120 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

60 enrolled 10 charts

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT01237054 2026-02-06

Imaging in MGUS, SMM and MM

31 enrolled 13 charts

Phase EARLY_PHASE1 Active not recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT02603887 2026-01-29

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

20 enrolled 12 charts

Smoldering Multiple Myeloma

NCT03839459 2026-01-28

Denosumab for Smoldering Multiple Myeloma

20 enrolled 8 charts

Phase NA Not yet recruiting

Smoldering Multiple Myeloma

NCT07305662 2026-01-21

KORMED-PA Stud

20 enrolled

Phase EARLY_PHASE1 Active not recruiting

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT04370483 2026-01-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

1 enrolled

Phase EARLY_PHASE1 Completed

Smoldering Multiple Myeloma

NCT03631043 2025-12-19

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

30 enrolled

Smoldering Multiple Myeloma

NCT05312255 2025-12-01

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

175 enrolled

Phase 3 Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT01169337 2025-11-25

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

226 enrolled 16 charts

Phase 3 Active not recruiting

Smoldering Multiple Myeloma

NCT00114101 2025-11-24

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

460 enrolled 11 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06055894 2025-11-13

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

200 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT05565638 2025-09-25

PROFAST

Phase NA Completed

23 enrolled

Smoldering Multiple Myeloma, Fasting, Multiple Myeloma, Weight Loss

NCT04776395 2025-09-15

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

68 enrolled

Phase NA Active not recruiting

Smoldering Multiple Myeloma

NCT04920084 2025-09-09

A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

23 enrolled 9 charts

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Phase 2 Terminated

17 enrolled 9 charts

Phase NA Active not recruiting

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05831358 2025-08-17

Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program

201 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma

NCT02916771 2025-08-11

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

61 enrolled 12 charts

Smoldering Multiple Myeloma

NCT05841550 2025-08-05

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Phase 1/2 Recruiting

20 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT06762769 2025-08-01

MODIFY

63 enrolled

Smoldering Multiple Myeloma

NCT00112827 2025-06-06

Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Completed

54 enrolled 13 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT02316106 2025-04-27

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

123 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05469893 2025-04-24

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

52 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03792763 2025-02-11

DEFENCE

8 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma

NCT05597345 2025-02-10

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

15 enrolled

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

NCT06183489 2024-10-18

ERASMM

50 enrolled

Smoldering Multiple Myeloma

NCT04731844 2024-07-12

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Phase NA Active not recruiting

40 enrolled

GenitourinaryPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prostatic Neoplasms

NCT04144387 2024-03-06

CARRISMM

395 enrolled

Smoldering Multiple Myeloma

NCT03289299 2023-12-12

ASCENT

87 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT03673826 2023-11-01

HO147SMM

58 enrolled

Phase EARLY_PHASE1 Withdrawn

Smoldering Multiple Myeloma

NCT03591614 2023-08-18

Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma

Smoldering Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT02903381 2023-06-13

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

8 enrolled 16 charts

Smoldering Multiple Myeloma

NCT02279394 2023-06-09

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

51 enrolled 14 charts

Smoldering Multiple Myeloma

NCT01838369 2023-01-11

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

Phase 2 Terminated

4 enrolled

Smoldering Multiple Myeloma

NCT02415413 2022-09-10

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

90 enrolled

Smoldering Multiple Myeloma

NCT03850522 2022-04-15

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Phase 2 Terminated

6 enrolled

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT01302886 2020-12-17

Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

41 enrolled